Cynthia Sandoval, PhD
Senior Director, Clinical Biomarker Development Eli Lilly
Seminars
Thursday 5th February 2026
New Frontiers in Plasma-Based Diagnostics for Alzheimer’s Evaluation
3:50 pm
- Advancements in Alzheimer’s Diagnostics: The presentation explores the multi-step process of diagnosing Alzheimer’s Disease (AD), emphasizing the role of various clinicians and the use of CSF testing and PET neuroimaging, and the overall importance of biomarkers in evaluating AD pathology
- Biomarker Innovations and Applications: The presentation delves into the progress towards a biological definition of AD, categorizing biomarkers into amyloid plaques, tau, and neurodegeneration. It discusses the emerging use of blood-based biomarkers (BBMs) for evaluating AD pathology, including their advantages, challenges, and the need for standardization in plasma biomarker testing
- Future Directions and Recommendations: The presentation outlines the rationale for focusing on specific plasma markers like P-tau217, the performance recommendations for BBMs, and the dual cut-point approach to achieve high sensitivity and specificity. It also presents data on commercially available plasma P-tau217 tests and recent updates to guidelines
